File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Update on yttrium-90-based radio-embolization for treatment of hepatocellular carcinoma

TitleUpdate on yttrium-90-based radio-embolization for treatment of hepatocellular carcinoma
Authors
KeywordsEmbolization
HCC
Review
TACE
Yttrium
Issue Date2012
PublisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ANS
Citation
ANZ Journal of Surgery, 2012, v. 82 n. 7-8, p. 505-509 How to Cite?
AbstractBACKGROUND: Catheter-based intra-arterial therapies provided effective tumour control for unresectable hepatocellular carcinoma without distant metastasis. There was a renewed interest in the advancement of yttrium-90 radio-embolization. METHOD: An extensive search on the MEDLINE databases identified seven case series and two comparative studies regarding yttrium-90 radio-embolization. RESULTS: Case series on yttrium-90 radio-embolization indicated a tumour response rate that ranged from 20% to 70%, and median survival that ranged from 7.7 to 26.6 months. Two comparative studies did not demonstrate significant difference in terms of tumour response rate and survival. One of these comparative studies demonstrated a statistically significant reduction in treatment-related neutropaenia. CONCLUSION: The current use of yttrium-90 radio-embolization was mainly based on small case series. Yttrium-90 radio-embolization seemed equivalent to conventional chemo-embolization in terms of tumour response rate and survival benefit. Emerging evidence suggested that yttrium-90 radio-embolization may have a more favourable side effects profile, in particular in reducing the chance of neutropaenia. Cost and logistics arrangement were two important considerations in generalizing the application of yttrium-90 radio-embolization. © 2012 The Authors. ANZ Journal of Surgery © 2012 Royal Australasian College of Surgeons.
DescriptionReview article
Persistent Identifierhttp://hdl.handle.net/10722/164668
ISSN
2015 Impact Factor: 1.158
2015 SCImago Journal Rankings: 0.432
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKan, RWMen_US
dc.contributor.authorTsang, SHYen_US
dc.contributor.authorPoon, RTPen_US
dc.contributor.authorCheung, TTen_US
dc.date.accessioned2012-09-20T08:07:45Z-
dc.date.available2012-09-20T08:07:45Z-
dc.date.issued2012en_US
dc.identifier.citationANZ Journal of Surgery, 2012, v. 82 n. 7-8, p. 505-509en_US
dc.identifier.issn1445-1433-
dc.identifier.urihttp://hdl.handle.net/10722/164668-
dc.descriptionReview article-
dc.description.abstractBACKGROUND: Catheter-based intra-arterial therapies provided effective tumour control for unresectable hepatocellular carcinoma without distant metastasis. There was a renewed interest in the advancement of yttrium-90 radio-embolization. METHOD: An extensive search on the MEDLINE databases identified seven case series and two comparative studies regarding yttrium-90 radio-embolization. RESULTS: Case series on yttrium-90 radio-embolization indicated a tumour response rate that ranged from 20% to 70%, and median survival that ranged from 7.7 to 26.6 months. Two comparative studies did not demonstrate significant difference in terms of tumour response rate and survival. One of these comparative studies demonstrated a statistically significant reduction in treatment-related neutropaenia. CONCLUSION: The current use of yttrium-90 radio-embolization was mainly based on small case series. Yttrium-90 radio-embolization seemed equivalent to conventional chemo-embolization in terms of tumour response rate and survival benefit. Emerging evidence suggested that yttrium-90 radio-embolization may have a more favourable side effects profile, in particular in reducing the chance of neutropaenia. Cost and logistics arrangement were two important considerations in generalizing the application of yttrium-90 radio-embolization. © 2012 The Authors. ANZ Journal of Surgery © 2012 Royal Australasian College of Surgeons.-
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/ANS-
dc.relation.ispartofANZ Journal of Surgeryen_US
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subjectEmbolization-
dc.subjectHCC-
dc.subjectReview-
dc.subjectTACE-
dc.subjectYttrium-
dc.subject.meshCarcinoma, Hepatocellular - therapy-
dc.subject.meshEmbolization, Therapeutic - methods-
dc.subject.meshHumans-
dc.subject.meshLiver neoplasms - therapy-
dc.subject.meshYttrium radioisotopes - therapeutic use-
dc.titleUpdate on yttrium-90-based radio-embolization for treatment of hepatocellular carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1445-2197.2012.06121.x-
dc.identifier.pmid22747591-
dc.identifier.scopuseid_2-s2.0-84864759024-
dc.identifier.hkuros211135en_US
dc.identifier.volume82en_US
dc.identifier.issue7-8en_US
dc.identifier.spage505en_US
dc.identifier.epage509en_US
dc.identifier.isiWOS:000307163500009-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats